Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer

Myeong Geun Choi1, Yeon Joo Kim1, Jae Cheol Lee2, Jin Kyung Rho3 & Chang-Min Choi1,2

1 Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
2 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
3 Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Keywords
Biomarker; immunotherapy; natural killer cell; non-small cell lung cancer.

Abstract
Background: The establishment of biomarkers that can be used to predict the response to immunotherapy for malignancy is extremely important. In particular, noninvasive analysis of immune cells from peripheral blood before treatment has gained increased attention, and natural killer (NK) cell activity has been shown to be related to treatment response. Here, we aimed to confirm the relationship between the response to immunotherapy and NK cell activity.

Methods: In this prospective observational study, patients with advanced NSCLC who were scheduled for immunotherapy from October 2018 to December 2019 were enrolled. Baseline NK cell activity was compared according to the best clinical response to immunotherapy.

Results: A total of 54 patients with advanced NSCLC were enrolled, and 34 patients were analyzed. The baseline NK cell activity was significantly higher in the non-PD group than in the PD group (P = 0.002). At the cutoff level of ≥1200 pg/mL, baseline NK cell activity yielded a sensitivity of 80% and a specificity of 68.4% in predicting the response to immunotherapy (AUC = 0.8, P < 0.003). The median progression-free survival (PFS) was significantly better in the high NK group (P = 0.003), and correlation between baseline NK cell activity and PFS was also confirmed (r = 0.517, P = 0.002).

Conclusions: Baseline NK cell activity was related to the response to immunotherapy and the PFS. We suggest that NK cell activity from peripheral blood before immunotherapy is a noninvasive, simple, and novel way to predicting the treatment response in patients with NSCLC.

Key points

Significant findings of the study
• The response to immunotherapy was significantly better in patients with high baseline NK cell activity, and there was a significant correlation between baseline NK cell activity and PFS.

What this study adds
• This study demonstrates the efficacy of baseline NK cell activity from peripheral blood as a biomarker for predicting immunotherapy response.
Introduction

The efficacy of cancer immunotherapy has been confirmed in recent years in several malignant diseases, including non-small cell lung cancer (NSCLC), and has become an innovative treatment modality in patients with malignancy. In particular, checkpoint inhibitors targeting programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1), have received considerable interest, and their clinical utility is developing rapidly. PD-L1 is usually found in tumor cells, whereas PD-1 is found in immune cells, such as CD4 T cells, CD8 T cells, B cells, monocytes, dendritic cells, and NK cells. The use of PD-1/PD-L1 antibodies block these ligand-receptor interactions, while augmenting T cell proliferation, and consequently suppressing the antitumor response. In other words, by suppressing these checkpoint inhibitors, this negative regulation can be reversed and subsequently lead to reactivation of the antitumor immune response.

However, despite this concept, clinically, the response rates of checkpoint inhibitors are only about 20% and treatment often fails. Although the reasons for this lack of efficacy are somewhat unknown, it is thought to result from the complexity of the immune checkpoint pathway, as well as the diverse array of tumor escape mechanisms. Numerous studies have sought to predict the response to immunotherapy by measuring biomarkers such as PD-L1 expression, tumor mutational load, and T cell repertoire sequencing; however, recent studies have shown contrasting results. Furthermore, these biomarkers require invasive biopsy, have a heterogenous result according to biopsy site, and often carry a high cost and adverse events. Therefore, biomarkers that can be obtained noninvasively to predict the response to immunotherapy are urgently required.

As the host immune system is known to play an important role in the response to immunotherapy, the association between the response to immunotherapy and the characteristics of the immune cells from peripheral bloods, including subset composition, function, cytokines, and proteins has been revealed. Usually, the baseline or on treatment fraction of the effector T cells are associated with a good outcome for immunotherapy, while a high fraction of inhibitory T cells is related to poor outcome. PD-1/PD-L1 inhibitor kills tumor cells, which express human leukocyte antigen-1 (HLA-1), by increasing T cell activity; however, HLA-1 negative tumor cells can escape from immunotherapy through "missing self." Tumor cells that avoid T cell mediated killing can be recognized and killed by natural killer (NK) cells, an innate lymphocyte population with cytotoxic activity. Recent studies have examined PD-1 expression on NK cells, and it is known that the response to PD-1/PD-L1 inhibitors is related to NK cells.

In our previous study, the frequency and function of immune cells, including NK cells, in a total of nine patients were evaluated in order to determine biomarkers related to the early response to immunotherapy. To this end, we found that the baseline NK cell activity was significantly higher in the responders. The purpose of the current study was to confirm the relationship between the response to immunotherapy and NK cell activity, and to identify additional biomarkers related to the response to immunotherapy.

Methods

Study design and patients

This was a prospective cohort observational study conducted on patients with advanced NSCLC scheduled for immunotherapy from October 2018 to December 2019. All patients were pathologically diagnosed with NSCLC, and adult patients between the ages of 20 and 80 were enrolled. The exclusion criteria were those with an Eastern Cooperative Oncology Group (ECOG) performance score >2, and those accompanied by malignancy other than NSCLC within five years of the NSCLC diagnosis. Peripheral blood was collected from patients before and six weeks after the immunotherapy. The number of subjects in this preliminary study was calculated based on the study period and the number of patients who received immunotherapy prior to this study. All participants provided their written informed consent, and the study was approved by the Institutional Review Board of the Asan Medical Center (IRB No. 2018–0755).

Clinical response assessment and outcomes

The primary study outcome was the comparison of baseline NK cell activity according to the clinical response to immunotherapy. The response was evaluated using computed tomography (CT) scan and immune-related response criteria (irRC). Patients were included in the non-PD group if their best response was partial response (PR) or stable disease (SD), while patients were included in the PD group if the best response was progressive disease (PD). Unless the patient was unstable, the assessment of response was performed at least four weeks after the initiation of immunotherapy and re-evaluated every two or three cycles. If cancer progression was suspected by CT scan, pseudo-progression was ruled out with a consecutive CT scan.

The secondary endpoints were NK cell activity at six weeks, and the change in NK cell activity from baseline. The cutoff baseline NK cell activity and its sensitivity and specificity were evaluated for the best prediction of disease control with immunotherapy. The baseline characteristics that could affect the progression-free survival (PFS), such
as PD-L1 status, tumor mutational burden, epidermal growth factor receptor (EGFR) mutation, and complete blood count (CBC) profile, were also included as secondary outcomes.

**NK cell activity**

The NK cell activity was measured using the NK Vue kit (ATgen, Sungnam, Korea) according to the manufacturer’s instructions. When NK cells were exposed to a specific recombinant cytokine, Promoca (ATgen), the release of IFN-γ was measured by quantitative sandwich enzyme-linked immunosorbent assay (ELISA). The concentration of IFN-γ can be used as a surrogate marker to measure NK cell activity in peripheral blood. Briefly, 1 mL of whole blood was collected into a pre-supplied Promoca tube and gently inverted three times. The tube was then incubated for 24 hours in a chamber at a temperature of 37°C. A CODA microplate processor (Biorad, Hercules, CA) was used to measure the optical density (OD), and standard curves were created using seven standards in duplicate. The OD values were then entered into NK Vue software, and the results were calculated in pg/mL.

**Statistical analysis**

The data obtained from patients were used to analyze the baseline and demographic characteristics. Mann-Whitney U test was used to compare continuous variables, and Fisher’s exact test was used for categorical variables. Receiver operating characteristic (ROC) curve analysis was used to establish the cutoff value of NK cell activity to predict disease control or progression, as the best response to immunotherapy. Spearman correlation was used to analyze the relationship between PFS and baseline NK cell activity, and Kaplan-Meier estimation and Log-rank test were used for PFS and survival analysis. Univariate and multivariate hazard ratios were calculated using Cox regression analysis to investigate the baseline characteristics affecting PFS. A P-value < 0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS version 25.0 (IBM Corp., Armonk, NY, USA).

**Results**

**Patient baseline characteristics**

From October 2018 to December 2019, a total of 54 patients with advanced NSCLC who met the inclusion
and exclusion criteria were enrolled. Among them, baseline blood sampling was performed on 40 patients, and 34 patients received at least one response assessment after immunotherapy. Of these patients, six had PR as their best response, nine had SD, and 19 had PD. In the non-PD group and PD group, 12 and 14 patients, respectively, six-week follow-up blood sampling was conducted, and NK cell activity changes from baseline were analyzed (Fig 1).

The baseline characteristics of the non-PD group and PD group were similar (Table 1). The median age of patients from the non-PD group and PD group was 69 and 59 years old, respectively, but there was no significant difference. In both groups, the proportion of males was higher than that of females, and more than half of the patients were diagnosed with adenocarcinoma. Most patients had an ECOG performance score of 0 or 1, and the majority of patients had a smoking history. All patients received standalone immunotherapy as second- or later-line of treatment. Previous treatments were targeted therapy or standard chemotherapy, and immunotherapy was administered after the blood cells fully recovered from the previous treatment. The proportion of immunotherapy drugs administered to patients was similar among pembrolizumab, nivolumab, and atezolizumab. Approximately 20% of patients had an EGFR mutation, half of patients had wild-type, and approximately 30% of patients,

Table 1 Baseline characteristics

|                      | Total (n = 34) | Non-PD group (n = 15) | PD group (n = 19) | P-value |
|----------------------|---------------|-----------------------|-------------------|---------|
| Age, years (median)  | 64            | 69                    | 59                | 0.096†  |
| Sex, n (%)           |               |                       |                   | 1.000‡  |
| M                    | 26 (76.5)     | 12 (80)               | 14 (73.7)         |         |
| F                    | 8 (23.5)      | 3 (20)                | 5 (26.3)          |         |
| Morphology, n (%)    |               |                       |                   | 0.717‡  |
| Adenocarcinoma       | 20 (58.8)     | 8 (53.3)              | 12 (63.2)         |         |
| Squamous cell carcinoma | 13 (38.2) | 6 (40)                | 7 (36.8)          |         |
| Others               | 1 (2.9)       | 1 (6.7)               | 0 (0)             |         |
| ECOG score           |               |                       |                   | 1.000‡  |
| 0–1                  | 29 (85.3)     | 13 (86.7)             | 16 (84.2)         |         |
| 2                    | 5 (14.7)      | 2 (13.3)              | 3 (15.8)          |         |
| Smoking, n (%)       |               |                       |                   | 0.715‡  |
| Never                | 11 (32.4)     | 4 (26.7)              | 7 (36.8)          |         |
| Former               | 23 (67.6)     | 11 (73.3)             | 12 (63.2)         |         |
| Lines of prior therapy, n (%) |       |                       |                   | 0.920‡  |
| 1                    | 21 (61.8)     | 10 (66.7)             | 11 (57.9)         |         |
| 2                    | 6 (17.6)      | 2 (13.3)              | 4 (21.1)          |         |
| ≥3                   | 7 (20.6)      | 3 (20)                | 4 (21.1)          |         |
| Immunotherapy, n (%) |               |                       |                   | 0.355‡  |
| Pembrolizumab        | 12 (35.3)     | 4 (26.7)              | 8 (42.1)          |         |
| Nivolumab            | 7 (20.6)      | 5 (33.3)              | 2 (10.5)          |         |
| Atezolizumab         | 15 (44.1)     | 6 (40)                | 9 (47.4)          |         |
| EGFR mutation, n (%) |               |                       |                   | NA      |
| Mutation             | 7 (20.6)      | 3 (20)                | 4 (21.1)          |         |
| Wild-type            | 16 (47.1)     | 7 (46.7)              | 9 (47.4)          |         |
| Not done             | 11 (32.4)     | 5 (33.3)              | 6 (31.6)          |         |
| PD-L1 expression, n (%) |            |                       |                   | NA      |
| ≥50%                 | 8 (23.5)      | 2 (13.3)              | 6 (31.6)          |         |
| 1%–49%               | 9 (26.5)      | 7 (46.7)              | 2 (10.5)          |         |
| <1%                  | 8 (23.5)      | 3 (20)                | 5 (26.3)          |         |
| Unknown              | 9 (26.5)      | 3 (20)                | 6 (31.6)          |         |
| SP263                |               |                       |                   |         |
| ≥50%                 | 15 (44.1)     | 6 (40)                | 9 (47.4)          |         |
| 1%–49%               | 8 (23.5)      | 5 (33.3)              | 3 (15.8)          |         |
| <1%                  | 10 (29.4)     | 3 (20)                | 7 (36.8)          |         |
| Unknown              | 1 (2.9)       | 1 (6.7)               | 0 (0)             |         |
| Median PFS, days (IQR) | 65 (37, 146) | 185 (78, N/E)         | 38 (34, 49)       |         |
| Median OS, days (IQR) | 246 (105, N/E)| N/E (246, N/E)       | 146 (61, 438)     |         |

†Mann–Whitney U test. ‡Fisher’s exact test. ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; N/E, not estimable; OS, overall survival; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival.
including patients with squamous cell carcinoma, were not identified with EGFR status. PD-L1 expression was positive in most patients, and the distribution of patients according to expression frequency was similar between both groups.

**NK cell activity as a biomarker for predicting response to immunotherapy**

The baseline NK cell activity was significantly higher in the non-PD group than the PD group. (1946.00 pg/mL vs. 382.80 pg/mL, respectively; $P = 0.002$; Fig 2a) Follow-up NK cell activity six weeks after immunotherapy was also higher in the non-PD group than the PD group, but there was no statistical significance (898.25 pg/mL vs. 213.20 pg/mL, respectively; $P = 0.274$; Fig 2b) Both groups showed a decrease in NK cell activity six weeks from baseline, but there was no significant difference change in NK cell activity ($-347.65$ pg/mL vs. $-41.10$ pg/mL, respectively; $P = 0.106$; Fig 2c). The ROC curve for baseline NK cell activity used to predict the response to immunotherapy is shown in Fig 3. At a cutoff level of $\geq 1200$ pg/mL, the baseline NK cell activity yielded a sensitivity of 80% and a specificity of 68.4% in predicting controlled disease with immunotherapy (AUC = 0.8, $P < 0.003$). Therefore, baseline NK cell activity was considered to be a meaningful predictive tool.

**Baseline NK cell activity and survival**

The median follow-up period of all study participants was 246 days. The median PFS was 65 days in the total patients, 185 days in the non-PD group, and 38 days in the PD group, and 17 of 34 patients died during the follow-up period. The median overall survival (OS) was 246 days for all enrolled patients. Survival analysis was conducted in two groups; the high NK group, and the low NK group, divided by baseline NK cell activity based on 1200 pg/mL (Table 2 and Fig 4). The median PFS was significantly longer in the high NK group (78 days) compared to that of the low NK group (37 days) ($P = 0.003$). With regards to OS, the median OS was 269 days in the high NK group and 145 days in the low NK group, but there was no statistical significance ($P = 0.06$). A significant correlation was shown between
baseline NK cell activity and PFS, in which the PFS was longer and the baseline NK cell activity increased (r = 0.517, P = 0.002; Table 2). In contrast, no correlation was found between baseline NK cell activity and OS.

PD-L1 status and response to immunotherapy

PFS and OS according to PD-L1 status were also analyzed (Table S1 and Fig S1). Of the total patients, 24 were positive for PD-L1 and 10 were negative. The median PFS in PD-L1 positive patients was 66 days, and the median PFS in PD-L1 negative patients was 49 days. The OS of PD-L1 positive and negative patients was 269 and 246 days, respectively. The PFS and OS in PD-L1 positive patients were slightly longer than those observed in PD-L1 negative patients, but there was no statistical significance.

Univariate and multivariate analyses

Univariate and multivariate analyses were conducted on whether baseline characteristics, PD-L1 status, CBC profile, or NK cell activity affected the PFS (Table 3). The hazard ratio of patients with an ECOG PS score ≥2 was 1.428, whereas the hazard ratio was <1, with high tumor mutational burden or positivity for PD-L1, but no significant difference was observed. With regards to the CBC profile, the hazard ratio for a high neutrophil-lymphocyte ratio was 2.514, but no statistical significance was observed in multivariate analysis. If the baseline NK cell activity was ≥1200 pg/mL, the hazard ratio in multivariate analysis was 0.377 (P = 0.016).

Discussion

This study demonstrates the efficacy of baseline NK cell activity as a biomarker for predicting response to immunotherapy, in particular PD-1/PD-L1 inhibitors. The response to immunotherapy was significantly better in patients with high baseline NK cell activity, and there was significant correlation between baseline NK cell activity and PFS. We established the cutoff baseline NK cell activity as ≥1200 pg/mL, and showed that this could predict the response to immunotherapy using ROC curve analysis. Furthermore,
Table 3 Univariate and multivariate hazard ratios by Cox regression analysis for progression-free survival

| Variables | Progression-free survival |
|-----------|---------------------------|
|           | HR (95% CI) | p-value |
| **Univariate analysis** |
| Baseline characteristics | | |
| Age ≥60 | 0.617 (0.286, 1.333) | 0.219 |
| Sex, male | 0.784 (0.327, 1.881) | 0.586 |
| Morphology, adenocarcinoma | 1.022 (0.467, 2.237) | 0.957 |
| Ever smoker | 0.722 (0.329, 1.586) | 0.418 |
| ECOG score ≥2 | 1.428 (0.537, 3.796) | 0.475 |
| Lines of prior therapy ≥2 | 1.106 (0.505, 2.424) | 0.802 |
| EGFR, mutation | 1.035 (0.367, 2.922) | 0.948 |
| Tumor mutational burden >10 mut/Mb | 0.610 (0.161, 2.314) | 0.468 |
| **CBC profile** | | |
| ANC >7000 | 0.678 (0.314, 1.467) | 0.324 |
| AMC >630 | 0.993 (0.464, 2.212) | 0.985 |
| WBC >10 000 | 0.857 (0.295, 2.486) | 0.776 |
| ALC >7000 | 0.647 (0.194, 2.156) | 0.478 |
| Platelet >450 000 | 0.548 (0.164, 1.834) | 0.329 |
| M/L >11.3 | 0.987 (0.132, 7.370) | 0.990 |
| M/L >11.3 | 0.987 (0.132, 7.370) | 0.990 |
| Platelet >450 000 | 0.548 (0.164, 1.834) | 0.329 |
| **NK activity** | | |
| Baseline NK activity ≥1200 pg/mL | 0.325 (0.150, 0.705) | 0.004 |
| **Multivariate analysis** | | |
| ALC/ANC ≥3.0 | 2.051 (0.918, 4.581) | 0.080 |
| Baseline NK activity ≥1200 pg/mL | 0.377 (0.170, 0.835) | 0.016 |

ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ALC/ANC, absolute lymphocyte count/absolute neutrophil count; HR, hazard ratio; M/L, monocyte/lymphocyte; WBC, white blood cell.

we were able to confirm that the PFS was improved in the high NK group, whose baseline NK cell was higher than this cutoff value, compared to the low NK group. Therefore, we suggest that physicians can easily and noninvasively predict response to immunotherapy, and make decisions on treatment regimens by obtaining peripheral blood from patients and measuring NK cell activity before treatment.

Traditionally, measuring biomarkers, such as PD-L1 expression and tumor mutational burden, to predict the response to immunotherapy have required invasive biopsy. In order to reduce this disadvantage, recent efforts have focused on establishing biomarkers from peripheral blood. Indeed, a previous study analyzed the outcome of immunotherapy according to immune cell count or frequency, including neutrophils, lymphocytes, and the neutrophil-lymphocyte ratio from peripheral blood. In patients with melanoma, the biomarker predicting response to PD-1/PD-L1 inhibitors was studied using flow cytometry analysis, and it was shown that NK cell subsets were associated with the response to immunotherapy. However, no previous study has examined the relationship between NK cell function in peripheral blood and the response to immunotherapy in patients with NSCLC. Therefore, our study was meaningful and pioneering in that it confirmed the possibility of a relationship between NK cells and response to immunotherapy. In addition, to prove the result by using response as categorical outcome, we utilized PFS as a continuous outcome. A cutoff value of NK cell activity to predict the response was also suggested.

So far, the mechanism underlying the relationship between NK cell activity and PD-1/PD-L1 inhibitors has not been revealed, although there are some hypotheses. In a mouse model, a PD-1/PD-L1 inhibitor augmented NK cell function, and NK cells with PD-1 expression were found to be the main responders to PD-1/PD-L1 inhibitors in patients with HLA-1 deficient tumors. Furthermore, it was shown that the greater the number of NK cells with PD-1 expression, the better response to the PD-1/PD-L1 inhibitor. In contrast, response to immunotherapy was worse in the NK-depleted group. Another hypothesis is that IFN-γ secreted by NK cells may increase the response to PD-1/PD-L1 inhibitors as a result of increased expression of PD-L1 in tumor cell. The results of this study can also be explained by these hypotheses, although further study is required to fully elucidate the mechanisms.

In addition to findings related to NK cell activity, we also demonstrated that patients with a neutrophil-lymphocyte ratio ≥3.0 were remarkably close to significance, with a hazard ratio of 2.5 in multivariate analysis. This result, similar to those of previous studies, supports that cytotoxic CD8 T cells are associated with a positive outcome, while neutrophil count is associated with a poor outcome. This suggests that a CBC profile conducted routinely before treatment may prove to be a useful tool to predict treatment response.

There are some limitations of this study. The first limitation was its small sample size; a total of 34 patients were finally analyzed in this preliminary study, and the results will need to be confirmed by large-scale studies in the future. Another limitation was the short-term study period. Although the correlation between NK cell activity and the best response or PFS was verified, the follow-up period was too short to demonstrate the relationship with OS. As such, additional studies with longer follow-up are required in the future. Moreover, the role of PD-L1 expression, which is already known as a predictive biomarker, was not demonstrated in this study, possibly due to the abovementioned limitations.

Furthermore, it would be better if the response to immunotherapy was further subdivided. For example, if the...
hyperprogression, which has recently been in the spotlight,\(^2^8\) were to be analyzed separately in the PD group, clinically meaningful results could be obtained. Although data were not shown, baseline NK cell activity from three patients, who initiated immunotherapy but were lost to follow-up before the response assessment, were measured low, with a mean of 78.13 pg/mL and a median of 53.6 pg/mL. If these patients were lost to follow-up because of poor outcome, such as hyperprogression, there would be a possibility that NK cell activity and hyperprogression are also related. In addition, a further limitation may exist in that the blood samples were only collected at two points. Therefore, further study with more follow-up blood sampling could reveal the association with change of measured values and prognosis.

PFS for all patients in this study was 65 days and shorter than the known PFS of immunotherapy.\(^1^–^3\) This is believed to be because the lines of treatment of these patients were second or later and had received various kinds of immunotherapy. In fact, the PFS for immunotherapy was 1.9–4.0 months in patients on second or above lines of treatment, and the PFS for nivolumab and atezolizumab was shorter than that for pembrolizumab.\(^2^9^–^32\) The proportion of treatment lines or kinds of immunotherapy in the two groups did not statistically differ in this study; however, these variables should be controlled in further studies. Finally, patients only received a PD-1/PD-L1 inhibitor, and it is necessary to perform further studies with immunotherapies other than PD-1/PD-L1 inhibitors.

In conclusion, baseline NK cell activity from patients with NSCLC was related to the response and PFS to immunotherapy. Therefore, we suggest that NK cell activity from peripheral blood before immunotherapy is a noninvasive, simple, and novel laboratory test for predicting response of treatment in patients with NSCLC. Future long-term and large-scale studies with various immunotherapies are required to confirm the efficacy of NK cell activity as a predictive biomarker for prognosis.

**Acknowledgments**

The authors would like to thank Enago (http://www.enago.co.kr) for the English language review.

**Disclosure**

The authors have no conflicts of interest to declare.

**References**

1. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non–small-cell lung cancer. *N Engl J Med* 2015; 372: 2018–28.

2. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. *N Engl J Med* 2015; 373: 1627–39.

3. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. *N Engl J Med* 2015; 373: 123–35.

4. Okazaki T, Honjo T. PD-1 and PD-1 ligands: From discovery to clinical application. *Int Immunol* 2007; 19: 813–24.

5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012; 12: 252–64.

6. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure). *Ann Oncol* 2016; 27: 1492–504.

7. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. *Mol Oncol* 2015; 9: 847–56.

8. Samstein RM, Lee C-H, Shoushtari AN et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* 2019; 51: 202–6.

9. Reuben A, Gittelman R, Gao J et al. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: An association with predicted neoantigen heterogeneity and postsurgical recurrence. *Cancer Discov* 2017; 7: 1088–97.

10. Yi M, Jiao D, Xu H et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. *Mol Cancer* 2018; 17: 129.

11. Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer. *Eur J Cancer* 2019; 106: 144–59.

12. Ren D, Hua Y, Yu B et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. *Mol Cancer* 2020; 19: 19.

13. Nixon AB, Schalper KA, Jacobs I, Poturi S, Wang IM, Fleenor C. Peripheral immune-based biomarkers in cancer immunotherapy: Can we realize their predictive potential? *J Immunother Cancer* 2019; 7: 325.

14. Kärre K. NK cells, MHC class I molecules and the missing self. *Scand J Immunol* 2002; 55: 221–8.

15. Hsu J, Hodgins JJ, Marathe M et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. *J Clin Invest* 2018; 128: 4654–68.

16. Pesce S, Greppi M, Grossi F et al. PD-1/PD-1s checkpoint: Insight on the potential role of NK cells. *Front Immunol* 2019; 10: 1242.

17. Cho YH, Choi MG, Kim DH et al. Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer. *Target Oncol* 2020; 15: 241–7.

18. Wolchok JD, Hoos A, Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. *Clin Cancer Res* 2009; 15: 7412–20.

19. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. *Lancet Oncol* 2016; 17: e542–e51.
20 Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med 2018; 50: 1–11.
21 Diem S, Schmid S, Krapf M et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111: 176–81.
22 Subrahmanyam PB, Dong Z, Gusenleitner D et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer 2018; 6: 18.
23 Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 2018; 7: e1509819.
24 Cavazzoni A, Digiacoimo G, Alfieri R et al. Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer. Cancers (Basel) 2020; 12: 666.
25 Qian J, Wang C, Wang B et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: Hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation 2018; 15: 290.
26 Capone M, Giannarelli D, Mallardo D et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 2018; 6: 74.
27 Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493–503.
28 Champiat S, Dercle L, Ammari S et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23: 1920–8.
29 Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004–12.
30 Rizvi NA, Mazières J, Planchar D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015; 16: 257–65.
31 Peters S, Gettinger S, Johnson ML et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017; 35: 2781–9.
32 Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540–50.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Figure S1 Kaplan–Meier curves according to PD-L1 expression. (a) Progression-free survival. (b) Overall survival. Table S1 Progression-free and overall survival according to PD-L1 expression.